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Roles of Bcl-3 in the Pathogenesis of Murine
Type 1 Diabetes
Qingguo Ruan, Shi-Jun Zheng, Scott Palmer, Ruaidhri J. Carmody, and Youhai H. Chen
OBJECTIVE—It has long been recognized that autoimmunity is
often associated with immunodeficiency. The mechanism under-
lying this paradox is not well understood. Bcl-3 (B-cell lymphoma
3) is an atypical member of the IB (inhibitor of the nuclear
factor-B) family that is required for lymphoid organogenesis
and germinal center responses. Mice deficient in Bcl-3 are
immunodeficient because of the microarchitectural defects of
their lymphoid organs. The goal of this study is to define the
potential roles of Bcl-3 in type 1 diabetes.
RESEARCH DESIGN AND METHODS—Bcl-3–deficient NOD
mice were generated by backcrossing Bcl-3–deficient C57BL/6
mice to NOD mice. Spontaneous and induced type 1 diabetes
were studied in these mice by both pathologic and immunologic
means. The effect of Bcl-3 on inflammatory gene transcription
was evaluated in a promoter reporter assay.
RESULTS—We found that Bcl-3–deficient NOD and C57BL/6
mice were, paradoxically, more susceptible to autoimmune dia-
betes than wild-type mice. The increase in diabetes susceptibility
was caused by Bcl-3 deficiency in hematopoietic cells but not
nonhematopoietic cells. Bcl-3 deficiency did not significantly
affect anti-islet Th1 or Th2 autoimmune responses, but markedly
increased inflammatory chemokine and T helper 17 (Th17)-type
cytokine expression. Upon transfection, Bcl-3 significantly inhib-
ited the promoter activities of inflammatory chemokine and
cytokine genes.
CONCLUSIONS—These results indicate that in addition to
mediating lymphoid organogenesis, Bcl-3 prevents autoimmune
diabetes by inhibiting inflammatory chemokine and cytokine
gene transcription. Thus, a single Bcl3 gene mutation leads to
both autoimmunity and immunodeficiency. Diabetes 59:2549–
2557, 2010
Type 1 diabetes, or insulin-dependent diabetes, isan inflammatory disease of the pancreatic isletsthat afflicts millions of people worldwide. Al-though the genetic and environmental factors
that trigger the disease vary, the common pathologic
outcome of type 1 diabetes is the destruction of insulin-
producing -cells by inflammatory cells (activated lym-
phoid and myeloid cells) through a process called insulitis.
Development of insulitis requires coordinated expression
of a large number of genes that mediate the activation,
migration and effector functions of inflammatory cells
(1,2). These include genes that encode cytokines, chemo-
kines, and cytotoxic enzymes. Although it is well recog-
nized that expression of these genes is tightly controlled at
the transcriptional level, the nature of the transcription
factors involved and the mechanisms of their action in
type 1 diabetes are not well understood. Recent studies
from several laboratories, including ours, indicate that the
nuclear factor-B (NF-B) family of transcription factors
plays crucial roles in type 1 diabetes. Thus, in both mice
and humans, type 1 diabetes is associated with heightened
NF-B activation (3–6), whereas NF-B deficiency in mice
renders them resistant to the disease (7,8). Importantly,
inhibiting NF-B activities is highly effective in suppress-
ing models of type 1 diabetes (9–11). Therefore, NF-B has
emerged as a long sought-after transcriptional regulator of
type 1 diabetes.
In mammals, there are five NF-B genes, NFKB1,
NFKB2, RELA, cREL, and RELB, which in turn encode
seven proteins: p105, p50, p100, p52, p65 (RelA), c-Rel, and
RelB (12,13). The protein p50 is generated from limited
proteasomal processing of its p105 precursor, as is p52
from its p100 precursor. The p50 and p52 proteins lack the
transactivating domain found in the COOH-terminal re-
gions of other NF-B proteins. Therefore, their ho-
modimers function primarily as repressors of gene
transcription. The activities of NF-B are tightly regulated
by several IB (inhibitor of B) proteins that share high
sequence and structural homologies (14). These include
IB, IB, IB, IBε, IB, IBNS, and Bcl-3. Addition-
ally, the COOH-terminal regions of p100 and p105 also
serve as IBs. These IB proteins contain repeated se-
quences of 30 amino acids long termed ankyrin repeats,
which are essential for binding to NF-B. Unlike other IB
proteins that are located primarily in the cytoplasm, IB,
IBNS, and Bcl-3 are found mainly in the nucleus and
therefore are involved chiefly in regulating nuclear NF-B
activities. These nuclear IB proteins exhibit significant
differences in their NF-B binding. Bcl-3 binds to only p50
and p52 homodimers (15,16); IB binds to both p50
homodimers and p65/p50 dimers, whereas IBNS appears
to show little subunit preference (17,18). Importantly, the
nuclear IB proteins are not degraded after IKK (IB
kinase) activation, and their primary function appears to
be the modulation of gene transcription in a gene- and
NF-B subunit–specific manner. Bcl-3 has been reported
to be able to either activate or repress gene transcription
after binding to p50 or p52 homodimers (19–22). Mice
deficient in Bcl-3 are more susceptible to infectious dis-
eases because of developmental defects of their lymphoid
organs and reduced germinal center responses (23,24).
These defects appear to be caused by Bcl-3 deficiency in
nonhematopoietic stromal cells, and they reflect a role
of Bcl-3 in activating organogenic chemokine genes
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(25,26). Similar to p52, Bcl-3 may also regulate thymic
stromal cell development, indirectly controlling thymic
tolerance (26). On the other hand, Bcl-3 in combination
with p50 can inhibit cytokine gene expression after
Toll-like receptor (TLR) activation, preventing septic
shock (27). Here, we describe a novel role of Bcl-3 in
models of type 1 diabetes.
RESEARCH DESIGN AND METHODS
C57BL/6 (B6) mice that carry a Bcl3 gene mutation were generated as described
previously (24,28). NOD.BDC2.5 TCR transgenic mice and NOD.scid mice were
purchased from Jackson Laboratory (Bar Harbor, ME). To generate BDC2.5
transgenic mice with Bcl3 gene null mutation, Bcl3/ B6mice were crossed with
NOD.BDC2.5 transgenic mice, and progenies were genotyped for MHC and Bcl3
by PCR. BDC2.5 TCR expression was determined by flow cytometry using
monoclonal antibodies against CD4 and V4. The B6xNOD.BDC2.5 TCR trans-
genic mice used in this study were all H-2b/g7. Only wild-type littermates were
used as controls. To generate NODmicewith theBcl3 gene null mutation,Bcl3/
B6 mice were backcrossed to NOD mice for nine generations. All mice were
housed in the University of Pennsylvania animal care facilities under pathogen-
free conditions, and all procedures were preapproved by the Institutional Animal
Care and Use Committee.
Induction and evaluation of diabetes. To induce diabetes, B6 mice were
injected intraperitoneally for 5 consecutive days with 40 mg/kg/day of
streptozotocin, whereas NOD and BDC2.5 transgenic mice were injected
intraperitoneally with 200 mg/kg of cyclophosphamide once weekly for 2
weeks. Both streptozotocin and cyclophosphamide were purchased from
Sigma (St. Louis, MO). Mice were tested in a blinded manner every other day
for urinary glucose levels using the Keto-Diastix kit (Bayer, Elkhart, IN) and
every other week for blood glucose levels. They were considered diabetic if
the urinary glucose levels were 500 mg/dl or the blood glucose levels were
250 mg/dl on at least two consecutive tests. To obtain histologic profiles of
the pancreas, pancreatic sections were fixed in 10% formalin, embedded
in paraffin, sectioned, stained with hematoxylin/eosin, and examined by
microscopy.
Flow cytometry and antibodies. Flow cytometric analyses were performed
on freshly prepared splenocytes or CD4	 T-cells after Th17 cell differentiation
in vitro. For intracellular staining, cells were fixed in fixation and permeabi-
lization solution (BD Biosciences), and intracellular cytokine staining was
performed per the manufacturer’s protocol. Stained cells were analyzed on a
fluorescence-activated cell sorter-calibur (BD Biosciences). Data were ana-
lyzed with FlowJo software.
Cell culture and cytokine assay. For cytokine assays, splenocytes were
cultured at 1.5 
 106 cells/well in 0.2 ml of Dulbecco’s modified Eagle’s
medium (DMEM) with 10% FBS in the presence or absence of 20 g/ml GAD65
peptide or 50 g/ml insulin, anti-CD3 mAb, and/or anti-CD28 mAb. Culture
supernatants were collected 48 h later, and cytokine concentration was
determined by quantitative ELISA per the manufacturer’s recommendations.
All purified antibodies and recombinant cytokines were purchased from BD
Biosciences (San Diego, CA).
Real-time RT-PCR. Total RNA was extracted using TRIzol (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. Reverse tran-
scription was performed using oligo dT primers. Real-time PCR was per-
formed in an Applied Biosystems 7500 system using Power SYBR Green PCR
Master Mix or TaqMan Fast Universal PCR Master Mix (Applied Biosystems).
Relative levels of gene expression was determined using GAPDH as the
control. Taqman probe for TNF-, Rantes, and CCL5 were purchased from
Applied Biosystems. The primers for Eotaxin, MIP1, MIP1, IP10, interleukin
(IL)-17A, Aire, Foxp3, Fabp, and GAD65 were synthesized as previously
described (29).
Preparation of tissue extract. Spleen and pancreas were aseptically
removed from the mice and homogenized in RPMI-1640 containing 1% CHAPS
(3-[(3-cholamidopropyl)dimethyammonio]-1-propanesulfonate) (Calbiochem,
La Jolla, CA) at a ratio of 1:10 (wt/vol) using a Dounce grinder. The
homogenates were centrifuged at 2,000g for 20 min, and the supernatant was
collected and stored at 80°C before the cytokine assay.
Immunoblotting. Serially diluted tissue extract samples were spotted onto a
nitrocellulose membrane. The membrane was then blocked using 5% nonfat
milk in Tris-buffered saline Tween-20 (TBS-T), and incubated with 1:2,000
diluted rabbit anti–MCP-1 (eBioscience) or 1:1,000 diluted rabbit anti-Rantes
(eBioscience) and mouse anti–-actin for 30 min at room temperature. After
washing with TBS-T, the membrane was incubated with 1:20,000 diluted
secondary antibody conjugated with horseradish peroxidase at room temper-
ature for 30 min. Color was developed using ECL Western Blotting Detection
Reagents (Amersham Pharmacia Biotech).
Promoter luciferase assay. The pGL3-based murine p19 promoter construct
containing the genomic fragment 1,180 to 	110 of the p19 gene has been
previously described (30). The 2,730-bp genomic DNA (from 2,660 to 	70)
of the murine MCP1 promoter and 629-bp genomic DNA (from 569 to 	60)
of the murine IP10 promoter were cloned into the pGL3-basic vector
(Promega). Mouse full-length Bcl-3 cDNA was cloned into the pEF4 mamma-
lian expression vector. RAW264.7 cells were transiently transfected with p19,
MCP1, or IP10 promoter-luciferase construct together with the Bcl-3 expres-
sion vector or empty vector using Lipofectamine LTX transfection reagent
(Invitrogen). After 24 h, cells were treated with or without 200 ng/ml
lipopolysaccharide for 8 h, and the luciferase activities of the total cell lysates
were measured using the dual-luciferase reporter assay system (Promega).
Cotransfection of the Renilla-luciferase expression vector pRL-TK (Promega)
was used as an internal control for all reporter assays.
Th17 cell differentiation. Splenic CD4	 T-cells were purified by MACS
(Miltenyi Biotec) and cultured at 1.5 
 106/well in 24-well plates containing
plate-bound anti-CD3 (5 g/ml) and soluble anti-CD28 (1 g/ml) in DMEM
supplemented with 10% FBS, 10 units/ml mouse IL-2, 5 g/ml anti–IL-4 (BD
Pharmingen), 5 g/ml anti–-interferon (IFN-) (BD Pharmingen) with or
without 20 ng/ml IL-6 (BD Pharmingen), and 5 ng/ml TGF-1 (R&D Systems).
Three days later, cells were washed and treated for 4–5 h with 50 ng/ml
phorbol myristic acid (PMA) (Sigma) and 750 ng/ml ionomycin (Sigma) in the
presence of GolgiStop (1:1,500 dilution, BD Pharmingen) at 37°C before being
examined by flow cytometry.
Bone marrow and T-cell transfer. Bcl3/ mice have severe defects in the
microarchitecture of their secondary lymphoid organs, including reduced
germinal centers and follicular dendritic cell networks (23,24), which in turn
affect the immune competence of these animals. The structural defect is not
present in chimeric mice reconstituted with Bcl3/ bone marrow (25). In this
study, bone marrow chimeric mice were generated by irradiating wild-type or
Bcl3/ C57BL/6 mice twice with 500 rad spaced 3 h apart, followed by
intravenous injection of 107 bone marrow cells from wild-type or Bcl3/
C57BL/6 mice. Repopulation of the immune system was monitored by flow
cytometric analysis of the blood. As we reported, in the chimeric mice so
generated,90% of the T-cells and95% of the B-cells and myeloid cells were
derived from donor bone marrow 8–9 weeks after the cell transfer (31). For
T-cell transfer, 1.5 
 107 T-cells isolated from spleens were injected into
NOD.scid mice through the tail vein.
Statistical analysis. The significance of the differences in disease severity
and immune parameters was determined by the Kaplan-Meier test, paired
Student t test, or ANOVA.
RESULTS
Increased diabetes susceptibility of Bcl-3–deficient
NOD and C57BL/6 mice. To study the potential roles
of Bcl-3 in type 1 diabetes, we generated three strains
of Bcl-3–deficient mice: Bcl3/ C57BL/6, NOD, and
B6xNOD.BDC2.5 TCR transgenic mice as described in
RESEARCH DESIGN AND METHODS. NOD mice were monitored for
the development of spontaneous diabetes by weekly test-
ing of blood glucose levels. To induce diabetes in C57BL/6
and B6xNOD.BDC2.5 mice, we administered low-dose
streptozotocin and cyclophosphamide, respectively (Fig.
1). Age- and sex-matched wild-type littermates were used
as controls. As shown in Fig. 1A and B, 40% of C57BL/6
and B6xNOD.BDC2.5 mice developed diabetes. By con-
trast, the incidence of the disease was markedly increased
in Bcl3/ groups (80%). The NOD.BDC2.5 is a trans-
genic mouse line expressing the diabetogenic T-cell recep-
tor BDC2.5 in the NOD background. Young NOD.BDC2.5
mice are significantly more sensitive to cyclophospha-
mide-induced diabetes than their nontransgenic counter-
parts. It is a unique model of type 1 diabetes that is
different from B6 or conventional NOD mice in TCR usage
and incidence. Similarly, spontaneous diabetes was also
significantly accelerated in Bcl3/ NOD mice compared
with their wild-type controls (Fig. 1C). However, because
the incidence of spontaneous type 1 diabetes was very
high (80–85%) in wild-type NOD mice, the disease-promot-
ing effect of the Bcl3 gene mutation in this model was not
as striking as in other models.
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Consistent with these clinical findings, histochemical
analysis of pancreatic sections of wild-type and Bcl3/
mice revealed significant differences. Insulitis, character-
ized by peri- and intraislet infiltration by inflammatory
cells, was observed frequently in Bcl3/, but not wild-
type mice (Fig. 2). Taken together, these results indicate
that Bcl-3 plays a crucial role in preventing type 1 diabetes.
Increased Th17, but not Th1 or Th2, cytokine gene
expression in Bcl3/ mice. T-cells play important roles
in type 1 diabetes. To determine the potential effect of
Bcl-3 deficiency on T-cells during type 1 diabetes, we
examined their cytokine expression in vitro upon stimula-
tion with self-GAD65 peptide and insulin. We found that
Bcl3/ NOD splenocytes produced significantly more
Th17 (IL-17A and IL-6), but not Th1-(IL-2 and IFN-) or
Th2-type cytokines (IL-4 and IL-10) (Fig. 3A). Consistent
with this finding, IL-17A but not Th1- or Th2-type cytokines
was significantly increased in the blood and pancreas of 6-
to 8-week-old Bcl3/ NOD mice (Fig. 3B and data not
shown).
These results indicate that Bcl-3 may regulate Th17 cell
differentiation. To test this possibility, wild-type and
Bcl-3–deficient splenic CD4	 T-cells were purified and
cultured under Th17-inducing conditions (with anti–
IL-4, anti–IFN-, IL-6, and TGF-1) (Fig. 4A). Five days
later, cells were washed and restimulated with PMA and
ionomycin, stained with respective antibodies, and ex-
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FIG. 1. Bcl3/ NOD and C57BL/6 mice are more susceptible to type 1
diabetes. A: Bcl3/ (n  19) and Bcl3/ (n  15) C57BL/6 male mice
were injected with low-dose streptozotocin as described in RESEARCH
DESIGN AND METHODS. B: Bcl3/ (n  19) and Bcl3/ (n  8)
B6xNOD.BDC2.5 transgenic mice were injected with cyclophosphamide
as described in RESEARCH DESIGN AND METHODS. C: Bcl3/ (n  9) and
Bcl3/ (n  9) NOD mice were monitored for the development of
spontaneous diabetes for 32 weeks. Data presented are accumulated
diabetes incidence pooled from two independent experiments. The
differences between the two groups are statistically significant for all
panels, as determined by the Kaplan-Meier test.
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FIG. 2. Histologic profiles of pancreas. Mice were treated as described
in Fig. 1 and killed 45 days after the first streptozotocin (STZ) or
cyclophosphamide (CY) injection. Pancreata were collected, fixed in
10% formalin, and embedded in paraffin. Paraffin sections (5-m thick)
were stained with hematoxylin and eosin. Pancreatic sections of B6 (A)
and B6xNOD (C) Bcl3/ mice showed little or no insulitis, whereas
pancreatic sections of B6 (B) and B6xNOD (D) Bcl3/ mice showed
severe insulitis. Magnification: 200. E: Insulitis scores. Mice were
treated as in Fig. 1, and pancreatic inflammation was graded as follows:
0, no inflammation; 1, peri-insulitis with mononuclear cell infiltration
affecting 25% of the circumference; 2, peri-insulitis with mononuclear
cell infiltration affecting 25% of the circumference; 3, mild-to-moder-
ate insulitis with intraislet mononuclear cell filtration but good pres-
ervation of islet architecture; 4, severe insulitis with numerous
intraislet inflammatory cells and loss of normal islet architecture. (A
high-quality digital representation of this figure is available in the
online issue.)
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amined by flow cytometry. We found that Bcl-3 defi-
ciency did not significantly affect the differentiation of
Th17 cells. This indicates that the increased Th17 re-
sponse in Bcl-3–deficient mice is likely related to the
Bcl-3 effect on Th17 cell activation or survival, but not
differentiation. Consistent with this view, IL-23, a cyto-
kine important for Th17 cell expansion and survival,
was upregulated at both mRNA and protein levels in
Bcl3/ cultures (Fig. 4B). Thus, Bcl-3 may regulate
Th17 cell response through IL-23.
Increased chemokine gene expression in Bcl3/
mice. Chemokines play crucial roles in the development
of type 1 diabetes. To determine whether Bcl3 gene
mutation alters chemokine gene expression, we examined
the levels of chemokines in the spleen and pancreas of
Bcl3	/	 and Bcl3/ NOD mice. We found that the mRNAs
of MCP1, RANTES, IP10, and Eotaxin, but not those of
MIP1a, MIP1b, MIP2, or CCR7, were significantly in-
creased in the pancreata of Bcl3/mice, whereas those of
RANTES and MIP1 were also increased in the spleens of
Bcl3/ mice (Fig. 5A and data not shown). As expected,
proteins encoded by these genes were also increased in
Bcl3/ mice (Fig. 5B). Similarly, increased expression of
chemokines was also found in Bcl3/ CD4	 T-cells
treated with anti-CD3 antibody (Fig. 5C) and Bcl3/
insulin-specific T-cells (Fig. 5D). Although IP10, RANTES,
and MIP1b were early response genes, MCP1 was a late
response gene under these experimental conditions. These
results indicate that Bcl-3 plays a crucial role in controlling
chemokine gene expression in type 1 diabetes.
Repression of cytokine and chemokine gene promot-
ers by Bcl-3. Bcl-3 has been reported to be able to either
increase or decrease gene promoter activities. To deter-
mine the effect of Bcl-3 on the promoters of genes involved
in type 1 diabetes, we next performed promoter luciferase
reporter assays. RAW264.7 cells were transfected with
IL23p19, IP10, or MCP1 luciferase reporter construct,
together with a Bcl-3 expression construct. We found that
Bcl-3 transfection significantly decreased the promoter
activities of all these genes (Fig. 6). These results indicate
that Bcl-3 is able to repress inflammatory cytokine and
chemokine gene promoters.
Bcl-3 expressed by hematopoietic cells versus that
expressed by nonhematopoietic cells in type 1 diabetes.
Bcl-3 is constitutively expressed by both hematopoietic
and nonhematopoietic cells. Bcl-3 expressed by nonhema-
topoietic cells is important for lymphoid organogenesis,
but its role in autoimmunity is not clear. Experiments
presented in Fig. 1 do not directly address this issue
because Bcl-3 deficiency involved all cell lineages. To
elucidate lineage-specific roles of Bcl-3 in type 1 diabetes,
an experimental system in which Bcl-3 is selectively
depleted in one cell type but not others is needed. This can
be created by generating bone marrow chimeric mice in
which hematopoietic and nonhematopoietic cells are gen-
erated from different progenitor cells. Thus, chimeric mice
were generated by injecting Bcl3	/	 or Bcl3/ bone
marrow cells into irradiated Bcl3	/	 or Bcl3/ recipients
(Fig. 7A). Mice were then injected with low-dose strepto-
zotocin to induce diabetes. Bcl-3 deficiency in hematopoi-
etic cells significantly exacerbated the diabetes, whereas
Bcl-3 deficiency in nonhematopoietic cells had no effect on
the disease (Fig. 7A). The accumulated incidence of dia-
betes was increased from 67% in mice that received
wild-type bone marrow cells to 92% in mice that received
Bcl3/ bone marrow cells (P  0.02). Similarly, upon
adoptive transfer into NOD.scid mice, purified Bcl3/ T-
cells were significantly more effective than wild-type T-
cells in inducing spontaneous type 1 diabetes (Fig. 7B).
Taken together, these results indicate that Bcl-3 expressed
by hematopoietic cells, but not that expressed by nonhe-
matopoietic cells, prevents autoimmune diabetes.
Normal central tolerance in Bcl3/ mice. Mice doubly
deficient in Bcl-3 and NF-Bp52 have a severe defect in
thymic tolerance because of an arrest in thymic stroma
development and reduced self-antigen expressions in the
thymus, which can be corrected by wild-type thymic
transplants (26). Mice deficient in only Bcl-3 or NF-Bp52
do not suffer from thymic developmental disorders. Con-
* 
A 
B 
Serum Pancreas 
* 
IL
-2
 (p
g/
m
l)
IF
N-
γ (
ng
/m
l)
IF
N-
γ (
ng
/m
l)
IL
-1
7 
(p
g/
m
l)
IL
-6
 (p
g/
m
l)
IL
-1
0 
(p
g/
m
l)
IL
-4
 (p
g/
m
l)
IL
-1
7 
(p
g/
m
l)
IL
-1
7 
(p
g/
m
l)
IL
-1
7 
(p
g/
m
l)
Vehicle GAD65
0
50
100
150
WT
Bcl3-/-
Bcl3-/-
Bcl3-/- Bcl3-/-
Bcl3-/-
Bcl3-/-Bcl3-/-
Bcl3-/-
Bcl3-/-
Bcl3-/-
Vehicle GAD65
0
100
200
300 WT
Vehicle GAD65
0
20
40
60
80
WT
Vehicle GAD65
0
100
200
300
WT
* 
Vehicle GAD65
0
2000
4000
6000 WT
Vehicle GAD650
500
1000
1500 WT
0
4000
8000
WT
0
20
40
60 WT
* 
Vehicle Insulin
0
1000
2000
3000
4000
WT * 
Vehicle Insulin
0
20
40
60
WT
FIG. 3. Increased Th17, but not Th1 or Th2, type cytokines in Bcl3/
mice. A: Splenocytes from 6- to 8-week-old NOD mice (n  3) were
cultured with or without GAD65 peptide (20 g/ml) or insulin (50
g/ml) for 40 h. The cytokine concentrations in the culture superna-
tants were determined by ELISA. B: Sera and pancreatic extracts of
6- to 8-week-old NOD mice (n  3) were tested for IL-17A by ELISA.
*P < 0.01. Data presented are representative of two independent
experiments.
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sistent with this finding, quantitative PCR analysis of
thymus revealed that Bcl-3 deficiency did not affect
GAD65, fatty acid binding protein, or Aire expression (Fig.
8), indicating that the medullary thymic epithelial cells of
Bcl3/ mice developed normally. Furthermore, Foxp3
expression was not changed in Bcl3/ thymus (Fig. 8) or
anti-CD3–treated Bcl3/ CD4	 T-cells (data not shown),
indicating that Bcl-3 deficiency may not affect Treg cell
development.
DISCUSSION
The relationship between immunodeficiency and autoim-
munity is poorly understood. Our finding that Bcl-3–
deficient mice are more susceptible to autoimmune
diabetes despite their immunodeficient status provides a
rare opportunity to address this issue. On one hand, Bcl-3
is required for lymphoid organogenesis, and in its absence,
mice suffer from immunodeficiency as a result of disrupted
lymphoid organ microarchitecture. On the other hand, as
revealed from studies reported here, Bcl-3 is also required
for inhibiting inflammatory chemokine and Th17-type cy-
tokine expression. Bone marrow chimeric experiments
indicate that the immunodeficient status of Bcl3/ mice
resulted from Bcl-3 deficiency in stromal cells (25),
whereas increased autoimmunity was caused by Bcl-3
deficiency in hematopoietic cells (Fig. 7). Thus, by acting
through two different cell lineages, Bcl-3 controls both
lymphoid organogenesis and autoimmunity.
Bcl-3 has been reported to mediate IL-10–induced anti-
inflammatory effect by suppressing the expression of
IL-23p19 (32). Lipopolysaccharide-induced Bcl-3 expres-
sion was strongly impaired in IL10/ cells, which had
enhanced RelA binding to the IL23p19 promoter. Bcl-3
overexpression decreased lipopolysaccharide-induced IL-
23p19 gene expression (32). This is consistent with our
demonstration that Bcl-3 controlled the promoter activity
of IL23p19. Bcl-3 has also been previously reported to
regulate Th2 cell responses in anti-CD3–treated cultures
(33). Consistent with that report, we observed reduced
IL-4 production in anti-CD3–treated Bcl3/ T-cell cultures
(data not shown). However, GAD65-induced IL-4 produc-
tion was not affected by Bcl-3 deficiency (Fig. 3A), indi-
cating that the effect of Bcl-3 on Th2 cytokine expression
could be stimulus-specific.
Understanding the molecular mechanisms of type 1
diabetes requires investigation of at least two types of
genes: the susceptibility genes and the pathogenic genes.
The susceptibility genes are those that dictate who devel-
ops type 1 diabetes, whereas the pathogenic genes medi-
ate the insulitic process in those individuals who develop
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difference in the frequency of Th17 cells between the two groups is not statistically significant (P > 0.05). B and C: Bone marrow–derived
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the disease, although certain genes may fall into both
categories. Because type 1 diabetes is a multigenic disease
heavily influenced by environmental factors, correcting
the genetic defect in patients may have a limited impact on
the disease. By contrast, halting the function of pathogenic
genes may be more effective for controlling the disease.
Indeed, most immune therapeutic strategies developed for
type 1 diabetes target pathogenic genes or their products.
The NF-B family of transcription factors represents one
of the most attractive targets for anti-inflammatory ther-
apy. Because NF-B directly controls the expression of
multiple inflammatory genes, its blockade is more effective
for controlling inflammation than blocking one or a few
downstream inflammatory genes or proteins. The first-
generation Rel/NF-B drugs that block the entire Rel/
NF-B family have already been tested in both humans and
animals. These include proteasome inhibitors (e.g., the
FDA-approved PS-341), NF-B decoy oligodeoxynucleoti-
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des, and the nemo-binding domain peptides, which are
highly effective in preventing and treating models of
autoimmune diseases (9–11,34–40). Additionally, glu-
cocorticoids, which are currently used to control acute
inflammation, mediate their immunosuppressive effects, at
least in part, through inhibiting NF-B (glucocorticoids
upregulate IB expression and bind directly to NF-B).
Results reported here indicate that Bcl-3, a natural regu-
lator of NF-B, is critical for preventing type 1 diabetes,
and therefore may be harnessed to control the disease.
However, the precise molecular mechanisms through
which Bcl-3 inhibits type 1 diabetes need to be further
investigated. Although Bcl-3 may directly repress the pro-
moters of IL23p19, IP10, and MCP1 genes as we showed
in this study, whether it does so to other target genes
tested here is not clear. Additionally, although the in-
creased production of IL-17 and chemokines correlated
with the increased incidence of diabetes in Bcl3/ mice,
whether and to what degree these molecules contribute to
type 1 diabetes in this model remain to be established. The
latter issue may be difficult to address because multiple
cytokines and chemokines are likely regulated by Bcl-3 in
this model.
NOD mice spontaneously develop autoimmune diabetes
that shares many immunologic and pathologic features
with human type 1 diabetes (2,41). The disease is charac-
terized by mononuclear cell infiltration and subsequent
destruction of the pancreatic islets. Both lymphocytes and
myeloid cells play important roles in initiating and propa-
gating the autoimmune process. The incidence of the
disease is higher in female NOD mice than in males,
although it is heavily influenced by environmental condi-
tions. The cyclophosphamide-induced diabetes in NOD
mice used in this study is an accelerated model of type 1
diabetes. The disease can be precipitated by a single
injection of cyclophosphamide in young nondiabetic NOD
mice. Similar to spontaneous diabetes, it shares many
clinical and histologic features with human type 1 diabetes
and requires the participation of both T-cells and macro-
phages (42,43). Low-dose streptozotocin-induced diabetes
is another animal model for type 1 diabetes. Diabetes can
be induced in susceptible strains of mice or rats by
multiple injections of low doses of streptozotocin. Low-
dose streptozotocin-induced diabetes also shares many
clinical and histologic features with human type 1 diabetes
and may require the participation of both lymphocytes and
macrophages. However, the degree to which lymphocytes
contribute to diabetes in this model is not well under-
stood. It has been reported that mice deficient in T-cells
did not develop low-dose streptozotocin-induced diabetes
and that splenocytes from low-dose streptozotocin-admin-
istered mice were able to transfer the disease to normal or
immune-deficient recipients. On the other hand, low-dose
streptozotocin has also been reported to induce diabetes
in severe combined immunodeficient (SCID) mice that
Ve
ct
or
 
B
cl
-3
 
Ve
ct
or
 
B
cl
-3
 
Ve
ct
or
 
B
cl
-3
 
Ve
ct
or
 
B
cl
-3
 
   IP10       MCP1 
0
1
2
3 Unt
LPS
0
2
4
6
Unt
LPS
Pr
om
ot
er
 a
ct
iv
ity
 
(fo
ld
 in
cr
ea
se
) 
40 
30 
20 
10 
0 
IL23p19 
Pr
om
ot
er
 a
ct
iv
ity
 
(fo
ld
 in
cr
ea
se
) 
Ve
ct
or
 
B
cl
-3
 
p5
0 
Ve
ct
or
 
B
cl
-3
 
p5
0 
Unt
LPS
FIG. 6. Bcl-3 represses the promoter activities of IL23p19, IP10, and
MCP1 genes. RAW264.7 cells were transiently transfected with
IL23p19, IP10, and MCP1 promoter-luciferase constructs and the
expression vector for full-length Bcl-3 or p50, or the empty vector, as
indicated. After 24 h, cells were treated with or without lipopolysac-
charide for 8 h and the luciferase activities were measured. The
promoter activity is presented as fold increase over cells transfected
with Bcl-3 plasmid but not treated with lipopolysaccharide. All data
were normalized for transfection efficiency by dividing the activity of
the firefly luciferase by that of the Renilla luciferase. Data are repre-
sentative of three independent experiments.
A 
B 
P=0.02 D
ia
be
tic
 m
ic
e 
(%
) 
D
ia
be
tic
 m
ic
e 
(%
) 
P=0.002 
0 10 18 25 45
0
20
40
60
80
100
120
WT to WT
Bcl3-/- to WT
WT to Bcl3-/-
Days post STZ injection
0 2 4 6 8 10 12
0
20
40
60
80
100
120
WT to NOD.scid
Bcl3-/- to NOD.scid
Weeks post T cell transfer
FIG. 7. Bcl-3 deficiency in hematopoietic cells exacerbates type 1
diabetes. A: Bone marrow chimeric B6 mice were generated by injecting
wild-type or Bcl3/ bone marrow cells into wild-type or Bcl3/ mice
(n  12) as described in RESEARCH DESIGN AND METHODS. Eight weeks
later, mice were injected with low-dose streptozotocin to induce
diabetes. Mice were monitored for the development of diabetes for 45
days. Results are representative of two independent experiments. B: A
quantity of 1.5  107 splenic T-cells isolated from wild-type or Bcl3/
NOD mice were injected into NOD.scid mice (n  6–7) through the tail
vein. Mice were monitored for the development of spontaneous diabe-
tes for 11 weeks. Results are representative of two independent
experiments.
Q. RUAN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2555
have myeloid but not lymphoid cells (44,45). However,
scid gene mutation also increases the sensitivity of the
cells to apoptosis. Therefore, further studies are required
to elucidate the pathogenic mechanisms of diabetes in this
model. STZ may release nitric oxide (NO) upon degrada-
tion, which can directly induce -cell apoptosis. This may
in turn trigger the activation of macrophages and islet-
specific T-cells, leading to the destruction of more islet
cells. Results reported here indicate that Bcl-3 plays a
crucial role in both the NOD and the B6 models of type 1
diabetes. Therefore, a role of Bcl-3 in the development of
human type 1 diabetes needs to be determined.
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